West Pharmaceutical
756 hedge funds and large institutions have $18B invested in West Pharmaceutical in 2025 Q3 according to their latest regulatory filings, with 118 funds opening new positions, 270 increasing their positions, 248 reducing their positions, and 83 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
195% more call options, than puts
Call options by funds: $74.8M | Put options by funds: $25.4M
42% more first-time investments, than exits
New positions opened: 118 | Existing positions closed: 83
18% more capital invested
Capital invested by funds: $15.3B → $18B (+$2.69B)
4% more funds holding
Funds holding: 730 → 756 (+26)
9% more repeat investments, than reductions
Existing positions increased: 270 | Existing positions reduced: 248
1.85% less ownership
Funds ownership: 97.49% → 95.64% (-1.9%)
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$146M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$122M |
| 3 |
SCM
Steadfast Capital Management
New York
|
+$115M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$107M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$94.3M |
Top Sellers
| 1 |
Brown Advisory
Baltimore,
Maryland
|
-$127M |
| 2 |
Two Sigma Investments
New York
|
-$117M |
| 3 |
LIP
Liontrust Investment Partners
London,
United Kingdom
|
-$92.2M |
| 4 |
William Blair Investment Management
Chicago,
Illinois
|
-$79.1M |
| 5 |
Bank of New York Mellon
New York
|
-$73.3M |
WST Hedge Fund Activity: Q3 2025 in Review
756 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q3 2025, worth a combined $18B — up 18% from $15.3B a quarter earlier.
Buyers outnumbered sellers: 118 funds opened new WST positions and 83 closed out — a net gain of 35 holders — while 270 added to existing stakes and 248 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $146M. The largest seller was Brown Advisory, cutting an estimated $127M.
- 756 institutional investors held West Pharmaceutical (WST) as of Q3 2025, up from 730 in Q2 2025.
- Funds reported $18B of West Pharmaceutical stock for Q3 2025, up 18% quarter-over-quarter.
- 118 funds opened new West Pharmaceutical positions in Q3 2025 and 83 closed out, a net change of +35 holders.
- The largest West Pharmaceutical buyer in Q3 2025 was Citadel Advisors, an estimated $146M added.
- The largest West Pharmaceutical seller in Q3 2025 was Brown Advisory, an estimated $127M sold.
Based on aggregated 13F filings for Q3 2025.